Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis

被引:7
|
作者
Mori, Kazuma [1 ,8 ]
Akiyama, Yukinori [2 ]
Tanaka, Marenao [1 ]
Sato, Tatsuya [1 ,3 ]
Endo, Keisuke [1 ]
Hosaka, Itaru [4 ]
Hanawa, Nagisa [5 ]
Sakamoto, Naoya [6 ,7 ]
Furuhashi, Masato [1 ]
机构
[1] Sapporo Med Univ, Sch Med, Dept Cardiovasc Renal & Metab Med, S-1,W-16,Chuo Ku, Sapporo 0608543, Japan
[2] Sapporo Med Univ, Sch Med, Dept Neurosurg, Sapporo, Japan
[3] Sapporo Med Univ, Sch Med, Dept Cellular Physiol & Signal Transduct, Sapporo, Japan
[4] Sapporo Med Univ, Sch Med, Dept Cardiovasc Surg, Sapporo, Japan
[5] Keijinkai Maruyama Clin, Dept Hlth Checkup & Promot, Sapporo, Japan
[6] Hokkaido Univ, Fac Med, Dept Gastroenterol & Hepatol, Sapporo, Japan
[7] Grad Sch Med, Sapporo, Japan
[8] Natl Def Med Coll, Dept Immunol & Microbiol, Tokorozawa, Japan
基金
日本学术振兴会;
关键词
clustering; machine learning; metabolic dysfunction-associated fatty liver disease (MAFLD); metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); CLINICAL-PRACTICE GUIDELINES; DELPHI CONSENSUS STATEMENT; ALCOHOL-CONSUMPTION; HEPATITIS-C; INDEX; RISK; INDIVIDUALS; PREVALENCE; MECHANISMS; FACTORIAL;
D O I
10.1111/jgh.16552
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and AimNew nomenclature of steatotic liver disease (SLD) including metabolic dysfunction-associated SLD (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD) has recently been proposed. We investigated clustering analyses to decipher the complex landscape of SLD pathologies including the former nomenclature of nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD).MethodsJapanese individuals who received annual health checkups including abdominal ultrasonography (n = 15 788, men/women: 10 250/5538, mean age: 49 years) were recruited.ResultsThe numbers of individuals with SLD, MASLD, MetALD, ALD, NAFLD, and MAFLD were 5603 (35.5%), 4227 (26.8%), 795 (5.0%), 324 (2.1%), 3982 (25.8%), and 4946 (31.3%), respectively. Clustering analyses using t-distributed stochastic neighbor embedding and K-means to visually represent interconnections in SLDs uncovered five cluster formations. MASLD and NAFLD mainly shared three clusters including (i) low alcohol intake with relatively low-grade obesity; (ii) obesity with dyslipidemia; and (iii) dysfunction of glucose metabolism. Both MetALD and ALD displayed one distinct cluster intertwined with alcohol consumption. MAFLD widely shared all of the five clusters. In machine learning-based analyses using algorithms of random forest and extreme gradient boosting and receiver operating characteristic curve analyses, fatty liver index (FLI), calculated by body mass index, waist circumference, and levels of gamma-glutamyl transferase and triglycerides, was selected as a useful feature for SLDs.ConclusionsThe new nomenclature of SLDs is useful for obtaining a better understanding of liver pathologies and for providing valuable insights into predictive factors and the dynamic interplay of diseases. FLI may be a noninvasive predictive marker for detection of SLDs. 1 image
引用
收藏
页码:1382 / 1393
页数:12
相关论文
共 50 条
  • [21] Sarcopenia and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
    Abenavoli, Ludovico
    Statsenko, Michael
    Scarlata, Giuseppe Guido Maria
    Morano, Domenico
    Myazin, Roman
    Emelyanov, Dmitriy
    LIVERS, 2024, 4 (04): : 495 - 506
  • [22] A healthy lifestyle is prospectively associated with lower onset of metabolic dysfunction-associated steatotic liver disease
    Grinshpan, Laura S.
    Haim, Yaara Even
    Ivancovsky-Wajcman, Dana
    Fliss-Isakov, Naomi
    Nov, Yuval
    Webb, Muriel
    Shibolet, Oren
    Kariv, Revital
    Zelber-Sagi, Shira
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (11)
  • [23] Predictors of Atherosclerotic Cardiovascular Disease Events in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
    Kawanaka, Miwa
    Nishino, Ken
    Kawada, Mayuko
    Ishii, Katsunori
    Tanikawa, Tomohiro
    Urata, Noriiyo
    Suehiro, Mitsuhiko
    Haruma, Ken
    Kawamoto, Hirofumi
    INTERNAL MEDICINE, 2024,
  • [24] Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
    Moon, Joon Ho
    Jeong, Seogsong
    Jang, Heejoon
    Koo, Bo Kyung
    Kim, Won
    ECLINICALMEDICINE, 2023, 65
  • [25] A data-driven approach to decode metabolic dysfunction-associated steatotic liver disease
    Ramos, Maria Jimenez
    Kendall, Timothy J.
    Drozdov, Ignat
    Fallowfield, Jonathan A.
    ANNALS OF HEPATOLOGY, 2024, 29 (02)
  • [26] Integrating behavioral interventions into a holistic approach to metabolic dysfunction-associated steatotic liver disease
    Righetti, Riccardo
    Cinque, Felice
    Volpe, Maria Teresa
    Sebastiani, Giada
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2024, 18 (07) : 303 - 313
  • [27] Trends and Disparities in Cardiovascular Disease in US Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Zhang, Yanbing
    Zhang, Xinge
    Huang, Chuiguo
    Zhu, Lei
    BIOMEDICINES, 2025, 13 (04)
  • [28] A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease
    Wajcman, Dana Ivancovsky
    Byrne, Christopher J.
    Dillon, John F.
    Brennan, Paul N.
    Villota-Rivas, Marcela
    Younossi, Zobair M.
    Allen, Alina M.
    Crespo, Javier
    Gerber, Lynn H.
    Lazarus, Jeffrey V.
    HEPATOLOGY, 2024,
  • [29] Celiac Disease, Gluten-Free Diet and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Cazac, Georgiana-Diana
    Mihai, Bogdan-Mircea
    Stefanescu, Gabriela
    Gilca-Blanariu, Georgiana-Emmanuela
    Mihai, Catalina
    Grigorescu, Elena-Daniela
    Onofriescu, Alina
    Lacatusu, Cristina-Mihaela
    NUTRIENTS, 2024, 16 (13)
  • [30] Evidence related to a vegetarian diet and metabolic dysfunction-associated steatotic liver disease: protocol for a scoping review
    Moss, Kasey
    Gitman, Victor
    Sanchez, M. Ines Pinto
    Oczkowski, Simon
    Armstrong, David
    Jayakumar, Saumya
    Karvellas, Constantine Jason
    Selzner, Nazia
    Dionne, Joanna
    BMJ OPEN, 2024, 14 (04):